Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (June 2017)

40 slides from Zynerba Pharmaceuticals's investor presentation, Jun 26, 2017

  1. Slide 1: Enrollment Complete in Three Phase 2 Trials

    Enrollment Complete in Three Phase 2 Trials 3 Osteoarthritis — STOP Epilepsy — STAR 1 Enrollment complete: 188 patients randomized (target was 180) Data in July/August 2017 Enrollment complete: 320 patients randomized (target was 300) Data in July/August 2017 Fragile X (FXS) — FAB-C Enrollment compl

  2. Slide 2: Company Highlights

    Company Highlights 4 A clinical-stage specialty pharmaceutical company pioneering the development and commercialization of patent-protected synthetic cannabinoid therapeutics for transdermal delivery Experienced team with deep expertise and proven track record of success in CNS and pain drug develop

  3. Slide 3: 2017 – A Transformational Year with Multiple Near-Term Milestones Expected

    2017 – A Transformational Year with Multiple Near-Term Milestones Expected from Robust Pipeline 5 ZYN002 patent protected through 2030 ZYN001 patent protected through 2031 Product Candidate Indication Preclinical Phase 1 Phase 2 Next Milestones ZYN001 – THC Pro-Drug Patch ZYN002 – CBD Gel Epilepsy i

  4. Slide 4: Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space

    Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space 6 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in reducing focal seizure

  5. Slide 5: Breadth of Therapeutic Opportunities

    Breadth of Therapeutic Opportunities 7 Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, mostly in the CNS and immune system. Δ9-tetrahydrocannabinol (Δ9-THC) Cannabidiol (CBD) Possible indications Fibromyalgia Neuropathic Pain Appetite Nausea and vo

  6. Slide 6: ZYN002 CBD Gel Clinical Program

    8 ZYN002 CBD Gel Clinical Program Developing synthetic CBD formulated as a patent-protected permeation-enhanced gel

  7. Slide 7: ZYN002 – CBD Gel

    ZYN002 – CBD Gel First and only patent-protected permeation-enhanced synthetic cannabidiol gel formulated for transdermal delivery The permeation enhancer in ZYN002 increases the delivery of CBD through the layers of the epidermis and into the circulatory system 9 CBD Delivery

  8. Slide 8: Transdermal ZYN002 vs. Oral CBD

    Transdermal ZYN002 vs. Oral CBD 10 Potential Benefits of Transdermal ZYN002 vs. Oral CBD More consistent, controlled and sustained plasma level Avoids first-pass metabolism in the liver Fewer drug-drug interactions Avoids the GI tract Very low incidence of gastrointestinal events Avoids degradation

  9. Slide 9: Transdermal CBD Avoids Degradation of CBD to THC

    Transdermal CBD Avoids Degradation of CBD to THC 11 In Vitro Study ZYN002 avoids the GI tract, maintains CBD at physiological pH and prevents degradation of CBD to THC CBD degraded to THC in simulated gastric fluid May lead to increased psychoactive effects from THC Study data (Merrick et al.) publi

  10. Slide 10: Phase 1 Trials Results

    Trials 1 day, 7 day, and 14 day trials Subjects 98 healthy volunteers (n= 70 ZYN002; n= 28 placebo) and 22 epilepsy patients (n=16 ZYN002; n=6 placebo) Dose Daily doses levels – 50 to 504 mg CBD in 1%, 2.5% and 4.2% concentrations Safety & Tolerability ZYN002 was safe and well-tolerated at all dose

  11. Slide 11: Why Are We Studying CBD in Epilepsy in Adults?

    Why Are We Studying CBD in Epilepsy in Adults? 13 Multiple in vitro, in vivo and clinical data sources help clarify the potential of CBD as monotherapy In vitro Causes concentration-related / region-dependent attenuation of eleptiform activity Inhibits voltage-gated sodium channels; interacts with T

  12. Slide 12: Why Are We Studying CBD in Epilepsy in Adults?

    Why Are We Studying CBD in Epilepsy in Adults? 14 Focal seizures are the most common epilepsy in adults Size of market in the U.S. is substantial ~ 2.4 million US adults with epilepsy ~ 1.5 million with focal seizures* Current AED regimens fail to control seizures in ~1/3 of patients New treatment o

  13. Slide 13: ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy

    ZYN002 Should Effectively Treat Focal Seizures in Refractory Epilepsy Based on Other CBD Trials 15 Lennox-Gastaut Syndrome Dravet Syndrome Refractory Epilepsy with Focal Seizures Type of Trial 2 Double Blind Placebo Controlled (3rd Party) Double Blind Placebo Controlled (3rd Party) STAR 1 and 2 – Un

  14. Slide 14: Recent NEJM Publication of GWPH Phase 3 Data Supports Use of CBD in Epilepsy

    Recent NEJM Publication of GWPH PH3 Data Supports Use of CBD in Epilepsy 16 Good news for the study of CBD in epilepsy Strong efficacy in Dravet Syndrome Encouraging efficacy in patients with countable partial seizures AE profile provides potential differentiation for ZYN002

  15. Slide 15: Epilepsy Phase 2 Clinical Trial Top Line Results Expected in July/August 2017

    Epilepsy Phase 2 Clinical Trial Top Line Results Expected in July/August 2017 17 ZYN002 High-Dose CBD 195 mg* ZYN002 Low-Dose CBD 97.5 mg* Placebo Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy *In 4.2% gel ZYN002 High-Dose

  16. Slide 16: STAR Efficacy Endpoints

    STAR 1 Efficacy Endpoints 18 Primary Endpoint: Median reduction in seizure frequency per 28-day period comparing baseline with the treatment period via daily seizure diary Secondary Endpoints Proportion of patients with ≥50% reduction from baseline in seizure frequency Percent change from baseline i

  17. Slide 17: STAR Baseline Information

    19 STAR 1 Baseline Information* AED Use Average=2.5 AEDs Median=3.0 AEDs Median Seizure Frequency† 11.0 (2-335) †Median Monthly *As of June 5, 2017 Anti-Epileptic Drug Patients n (%) Anti-Epileptic Drug Patients n (%) Levetiracetam 85 (45) Zonisamide 24 (13) Carbamazepine 78 (41) Perampanel 21 (11)

  18. Slide 18: STAR 1 & STAR 2 Enrollment Status

    20 STAR 1 & STAR 2 Enrollment Status* Patients n Screened 224 Randomized 188 Still in Baseline 0 Completed STAR 1 162 Enrolled into STAR 2 158 * As of June 19, 2017

  19. Slide 19: Why ZYN002 in Osteoarthritis?

    Why ZYN002 in Osteoarthritis? 21 CBD modulates the vanilloid TRPV1 receptor which mediates antinociceptive and anti-inflammatory effects Mono-arthritic rat model provides proof of concept* ZYN002 was applied for four days after inducing arthritis in rats Significant reductions in: Swelling of knee j

  20. Slide 20: Osteoarthritis Phase 2 Clinical Trial – STOP

    Osteoarthritis Phase 2 Clinical Trial – STOP Top Line Results Expected in July/August 2017 22 Synthetic Transdermal Cannabidiol for Treatment of Knee Pain due to Osteoarthritis ZYN002 High-Dose: CBD 250 mg* ZYN002 Low-Dose: CBD 125 mg* Placebo Washout Baseline 1 week Every 12 hours for 12 weeks 7-10

  21. Slide 21: STOP Efficacy Endpoints

    STOP 1 Efficacy Endpoints 23 Primary Endpoint: Change from baseline in the weekly mean of the 24-hour average worst pain score at Week 12 Secondary Endpoints Assessments Change from baseline in the WOMAC Pain, Stiffness, and Physical Function Subscales Weeks 4, 8, 12 Responder rate based on ≥30% red

  22. Slide 22: STOP Enrollment Status and Baseline Information

    24 STOP Enrollment Status and Baseline Information* Worst Knee Pain Score (During Baseline) Mean=6.8 *As of June 1, 2017 Patients n Screened 418 Randomized 320 Still in Baseline 0

  23. Slide 23: What is Fragile X Syndrome?

    What is Fragile X Syndrome? 25 Fragile X Syndrome Autism spectrum disorder Most common inherited intellectual disability Caused by a mutation in the Fragile X Mental Retardation gene located on the X chromosome Leads to dysregulation of the endocannabinoid pathway including the reduction in endogeno

  24. Slide 24: Why ZYN002 in Fragile X Syndrome?

    Why ZYN002 in Fragile X Syndrome? CBD may effectively treat Fragile X syndrome In mouse knock-out model, inhibition of the metabolism of 2-AG improves Fragile X syndrome symptoms CBD inhibits the metabolism of anandamide and 2-AG increasing availability of these cannabinoids CBD has strong anxiolyti

  25. Slide 25: Fragile X Phase 2 Clinical Trial – FAB-C

    Fragile X Phase 2 Clinical Trial – FAB-C Top Line Results Expected in September 2017 27 Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg* Daily Screening Titration Weeks 6 to 12 Day 1 to Week 6 Open label, doses of CBD 50 mg, 100 mg, or 250 mg* Daily *In 4.2% gel Enrollm

  26. Slide 26: FAB-C Outcome Measures

    FAB-C Outcome Measures 28 Changes in Anxiety, Depression and Mood vs. Baseline as Measured by the ADAMS Scale Primary Outcome Measure Secondary Outcome Measures Aberrant Behavior Checklist Visual Analog Scale (VAS) to Assess Hyperactivity / Impulsivity Quality of Sleep- Sleep onset, sleep time, nigh

  27. Slide 27: ZYN001 THC Pro-Drug Patch Clinical Program

    29 ZYN001 THC Pro-Drug Patch Clinical Program Studying a synthetic pro-drug of THC in a state-of-the-art drug-adhesive matrix transdermal patch

  28. Slide 28: ZYN001 – THC Pro-Drug Patch

    ZYN001 – THC Pro-Drug Patch 30 Patent-protected synthetic D-glyceric acid ester-Δ9-tetrahydrocannabinol in a transdermal patch Working with LTS Lohmann Therapie-Systeme AG to optimize the formulation of ZYN001 for use in a state of the art drug-adhesive matrix transdermal patch before initiating pha

  29. Slide 29: Why a Patch?

    Note: Based upon FDA approved patch products. These results are not indicative of any preclinical or clinical data for ZYN001. Why a Patch? 31 Requirement Purpose Non-oral Avoids first-pass metabolism with increased bioavailability and more consistent plasma levels Controlled More consistent, contro

  30. Slide 30: Why THC in Fibromyalgia?

    THC is a CB1 agonist Has an analgesic effect in chronic pain models Acts at many sites along pain transmission pathways Nabilone (THC analogue) in patients with fibromyalgia Third-party 4-week, randomized, double-blind, placebo-controlled trial (N=40) — significant decreases in pain scores on multip

  31. Slide 31: THC in Neuropathic Pain

    THC’s agonist effect on CB1 receptors modulates nociceptive thresholds by regulating neuronal activity Third-party randomized, double-blind, placebo-controlled crossover trial in diabetic peripheral neuropathy (DPN) demonstrated that THC is effective in reducing neuropathic pain 16 patients with DPN

  32. Slide 32: ZYN001 Phase 1 Clinical Trial Underway

    ZYN001 Phase 1 Clinical Trial Underway Phase 2 Initiation Expected in 2H17 34 24 hours 3.5 days 7 days Part 2: Multiple Dose Part 1: Single Dose 3:1 randomization, placebo controlled Multiple doses over 14 days Two formulations selected from Part 1 Multiple formulations of ZYN001 tested in each grou

  33. Slide 33: ZYN001 – THC Pro-Drug Patch Phase 1 Clinical Plan

    ZYN001 – THC Pro-Drug Patch Phase 1 Clinical Plan 35 Trial Patients Dosing PD Evaluations Timing Phase 1 program: Part 1: Single Rising Doses in Normal Subjects Pharmacokinetic profile and tolerability evaluation of multiple formulations of ZYN001 Part 2: Multiple Rising Doses in Normal Subjects Mul

  34. Slide 34: ZYN001 Preliminary Phase 2 Clinical Plan

    36 Note: Subject to change due to further regulatory, clinical and other considerations. Trial Patients Dosing Primary Endpoint Timing Efficacy and Tolerability in Patients with Fibromyalgia Double-blind, placebo-controlled 120 patients 12 weeks Change from baseline in Fibromyalgia Impact Questionna

  35. Slide 35: Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space

    Why Zynerba is a Compelling Investment Opportunity in the High-Growth Cannabinoid Space 38 We believe CBD gel for focal seizures is a significantly de-risked lead candidate Reliable animal models show efficacy of CBD in epilepsy Third party studies have shown activity of CBD in reducing focal seizur

  36. Slide 36: Proven Leadership in Transdermal Drug Development

    Proven Leadership in Transdermal Drug Development 39

  37. Slide 37: Scientific Advisors

    Jacqueline French, MD Professor of Neurology, NYU Langone Medical Center John Messenheimer, MD Consultant, Neurologist/Epileptologist, John Messenheimer PLLC Michael Rogawski, MD, PhD Professor of Neurology, UC Davis Center for Neuroscience Rodney Radtke, MD Professor of Neurology, Duke University M

  38. Slide 38: Investor Relations and Analyst Coverage

    Investor Relations 41 NASDAQ: ZYNE Analyst Coverage* Jefferies: Biren Amin, PhD Piper Jaffray: Charles C. Duncan, PhD Oppenheimer: Derek Archila H.C. Wainwright: Corey Davis, PhD Roth: Michael Higgins Canaccord Genuity: Arlinda Lee, PhD Cantor Fitzgerald: Elemer Piros, PhD Maxim: Gabrielle Zhou * No

  39. Slide 39: June 2017

    June 2017 A clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs

  40. Slide 40: Specialty pharmaceutical company dedicated to transdermal synthetic cannabinoid treatments

    je specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs June 2017

Zynerba Pharmaceuticals — Investor Presentation (June 2017) on 6ix